Tumor Lysis Syndrome

Tumor Lysis Syndrome (TLS) refers to the metabolic consequences of the break-up of a tumor within the body, generally on account of cytotoxic (i.e. chemotherapeutic) intervention. In other words, when a cancer patient receives treatment, the cancer cells that are killed release their contents into the bloodstream and throw the metabolic state of the blood out of balance. This is characterized by three serious conditions:

Hyperkalemia: This is a build-up of potassium in the blood, or higher-than-normal levels of potassium in the blood.

Hyperphosphatemia: This is a build-up of phosphates in the blood.

Hyperuricemia: This is a build-up of uric acid in the blood

In all cases, it is the role of the kidneys to clear these substances from the blood, which is why kidney failure is a very real concern when coping with TLS.

Risk Factors for TLS

The highest degree of risk for TLS derives from those tumors that are known to grow the fastest, chiefly because they are known to be most susceptible to chemotherapy and similar anti-cancer interventions. These tumors include:

-- Lymphoblastic Lymphoma
-- Burkitt's lymphoma
-- T-cell acute lymphoblastic leukemia

Lower risk tumors include:
-- Low grade lymphomas
-- Small cell carcinomas
-- Breast carcinomas
-- Multiple myelomas

Other risk factors include:

-- Bulky disease
-- Hepatosplenomegaly (the swelling of the liver and the spleen beyond normal size)
-- High leukocyte count
-- Elevated LDH levels (pre-treatment)
-- Elevated levels of uric acid (pre-treatment)
-- Compromised kidney functions
-- Decreased urine output

Treatment strategies

There are several treatment strategies for Tumor Lysis Syndrome, and the subject is far too extensive for the scope of this entry. However, patients should be made aware by their physicians if they are at higher risk of developing TLS following anti-cancer treatment, and if so, what prophylactic measures can be taken to prevent the syndrome from developing in the first place.


Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. 2007. New York: McGraw Hill, Medical Publishing Division.
PubMed Health: Hyperkalemia
MedlinePlus: Hepatomegaly

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...